a1

1. (Amended) A method of treating a disease condition in a subject [~~by vasodilation or vasorelaxation~~] comprising:

~~selecting a subject; and~~

B

B

administering a mixture of L-arginine and an inhibitor of Hmg-CoA reductase to said subject[;

~~obtaining periodic indicators of vasorelaxations for the subject; and~~

continuing ~~administration~~ of the mixture until a desirable state of vasorelaxation is obtained].

a2

3. (Amended) The method of claim 1, wherein said disease condition is hypertension, hypertensive heart disease, coronary heart disease, cardiovascular disease, cerebrovascular disease, and renovascular disease.

Please cancel claims 7-11 without prejudice to presentation in this or a later filed case.

Please amend claim 12 as follows:

a3

12. (Amended) A therapeutic mixture of [an agonist of NOS and] a substrate of NOS and an inhibitor of Hmg-CoA reductase.

Please cancel claims 14-15.

Please amend claims 16-18 as follows:

a4

16. (Amended) A method of stimulating Nitric Oxide Synthase[to produce nitric oxide], said method comprising:

4th cont

administering L-arginine and an Hmg-CoA reductase inhibitor [agonist of nitric oxide synthase to a subject having a nitric oxide synthase receptor site, said agonist being different than L-arginine and being selected from the group consisting of:

lovastatin;

pravastatin;

simvastatin;

fluvastatin;

dalvastatin;

compactin;

HR-780;

BMY 22,089;

BMY 22,566;

SQ 33,600;

GR 95,030; or

CI 981;

stimulating said nitric oxide synthase to a desirable level with said agonist of nitric oxide synthase].

17. (Amended) The method of claim 16, wherein said L-arginine is

A4 cont'd

in excess to said [agonist] Hmg-CoA reductase inhibitor.

18. (Amended) The method of claim 16, wherein a therapeutically effective [amounts] amount of said L-arginine is combined with a therapeutically effective [amounts] amount of said [agonist] Hmg-CoA reductase inhibitor prior to [administering to the patient] said administration.

Please add the following new claims:

A5

19. (New) The method of claim 1, further including the step of obtaining periodic indicators of vasorelaxations for the subject; and continuing administration of the mixture until a desirable state of vasorelaxation is obtained.

20. (New) The method of claim 1 wherein said inhibitor of Hmg-CoA reductase is atorvastatin.

21. (New) The method of claim 1 wherein said inhibitor of Hmg-CoA reductase is cerivastatin.

22. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is an agonist of NOS.

23. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is atorvastatin.

24. (New) The therapeutic mixture of claim 13, wherein said inhibitor of Hmg-CoA reductase is atorvastatin and said biological equivalent of L-arginine is L-arginine.

25. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is cerivastatin.

26. (New) The therapeutic mixture of claim 13, wherein said